Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on new opioid analgesic labeling changes to give providers better information for how to properly taper patients who are physically dependent on opioids

SILVER SPRING: U.S. Food and Drug Administration has issued the following press release: As the Department of Health and Human Services (HHS) continues to make progress against the opioid crisis, [...]